The clinical information you need, at your fingertips.

Broker commissions more than doubled over eight years, with renewals, not new enrollments, now driving most of the spending. . .

Tecentriq (atezolizumab) gains a new adjuvant indication for patients with circulating tumor DNA (ctDNA) molecular residual disease after cystectomy. . .

Adding four weeks of buprenorphine after ketamine maintained and deepened reductions in suicidal ideation in adults with treatment-resistant depression, in a small randomized trial. . .

Small proof-of-concept trial suggests IL-6 blockade may improve depressive symptoms and fatigue in patients with elevated inflammation. . .

Oral ensitrelvir reduced symptomatic COVID-19 by two-thirds among household contacts in a global phase 3 trial. . .

Inqovi (decitabine and cedazuridine) plus venetoclax offers a new option for older adults and patients with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy. . .

Practice acquisitions were tied to more patients seen, more services delivered, and larger clinical teams under Medicare's fee-for-service payments. That’s a different pattern than has been documented in PE-owned hospitals and nursing homes. . .

Four major societies have refreshed joint guidance on the skills required to lead antimicrobial stewardship programs (ASPs), reflecting how much the role has grown since 2014. . .

The primary care physician shortage may reflect a healthcare system that rewards hospital and specialty care and not simply too few trainees entering the pipeline. . .